Meta AnalysisID 2515
支气管肺泡灌洗液半乳甘露聚糖检测用于免疫功能低下患者侵袭性曲霉病的诊断 [Cochrane方案]
CRD42017082781
To assess the diagnostic accuracy of galactomannan detection in BAL for the diagnosis of invasive pulmonary aspergillosis in people who are immunocompromised, at different cut-off values for test positivity, in accordanc
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2515
- Evidence Id
- 11073
- Core Evidence Id
- 11073
- Source Meta Analysis Id
- 2466
- Herb2 Meta Analysis Id
- HBMA002466
- Crd Id
- CRD42017082781
- Title
- Galactomannan detection in broncho-alveolar lavage fluid for invasive aspergillosis in immunocompromised patients [Cochrane protocol]
- Review Question
- To assess the diagnostic accuracy of galactomannan detection in BAL for the diagnosis of invasive pulmonary aspergillosis in people who are immunocompromised, at different cut-off values for test positivity, in accordance with the Cochrane Diagnostic Test Accuracy Handbook.<secondary_objectives modified=2016-06-19 11:10:17 +0100 modified_by=[Empty name]> Our secondary objective is to study several possible sources of heterogeneity, see '<link tag=HETEROGENEITY_ASSESSMENT type=SECTION/>Investigations of heterogeneity'. </secondary_objectives>
- Study Type Included
- Eligible studies will be those that assessed the diagnostic accuracy of galactomannan detection in BAL. The galactomannan ELISA can be assessed alone or in comparison to other tests.
- Condition Being Studied
- Invasive aspergillosis (IA) is a common and life-threatening opportunistic mycosis. Mortality in people diagnosed with this condition varies depending on the clinical setting, but ranges from 30% to 70% (<link ref=REF-Aisner-1977 type=REFERENCE/>Aisner 1977; <link ref=REF-Robenshtok-2007 type=REFERENCE/>Robenshtok 2007; <link ref=REF-von-Eiff-1995 type=REFERENCE/>von Eiff 1995). IA is caused by ubiquitous spores of Aspergillus spp., inhaled by everyone on a daily basis, which can cause invasive disease in the case of a failing immune system (<link ref=REF-Chotirmall-2013 type=REFERENCE/>Chotirmall 2013). As invasive aspergillosis only occurs in people with immune deficiency the incidence varies, depending on the degree of immune deficiency. In people who are highly immune deficient, such as people with acute myeloid leukaemia receiving highly intensive chemotherapy, the incidence can exceed 5%. Mainly because of the increasing application of immunosuppressive treatments, especially highly intensive chemotherapy, prolonged corticosteroid therapy and stem cell transplantation (<link ref=REF-Kaneko-2001 type=REFERENCE/>Kaneko 2001; <link ref=REF-Rubio-2009 type=REFERENCE/>Rubio 2009), the incidence is increasing. Most often the lungs or airways (or both) are the site of infection. But invasive aspergillosis can also occur in the nasal sinus, central nervous system, skin, gastro-intestinal tract, the deep structures of the eye, and prosthetic heart valves; or may give rise to a disseminated infection.
- Participant
- Participants that have been tested to diagnose or exclude IA using galactomannan detection in BAL.
- Animal
- Human Disease Modelled
- Intervention
- The commercially available galactomannan sandwich ELISA (Platelia™) performed on BAL will be the test under evaluation. Studies addressing detection in serum and other body fluids will be excluded.
- Comparator Control
- Reference standards The following reference standards will be used to define the target condition: positive culture from autopsy specimens with histopathological evidence of aspergillosis proving IA; the EORTC/MSG criteria.</ul>
- Main Outcome
- Diagnostic test accuracy
- Outcome Measure
- Additional Outcome
- Study Method
- Diagnostic, Systematic review
- Keyword
- Bronchoalveolar Lavage Fluid; Humans; Immunocompromised Host; Invasive Pulmonary Aspergillosis; Mannans; galactomannan
- Contact
- Koen de Heer [email protected]
- Organisational Affiliation
- The Cochrane Collaboration http://www.cochrane.org/
- Funding Source
- The authors declare that no such funding was received for this systematic review The authors declare that no such funding was received for this systematic review
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012399/abstract
- Review Type
- Language
- English
- Country
- Netherlands
- Review Stage
- Review Ongoing
- First Submission Date
- Registration Date
- 2017-12-02
- Anticipated Start Date
- 2016-10-15
- Anticipated Completion Date
- 2017-12-18
- Title Cn
- 支气管肺泡灌洗液半乳甘露聚糖检测用于免疫功能低下患者侵袭性曲霉病的诊断 [Cochrane方案]
- Title En
- Galactomannan detection in broncho-alveolar lavage fluid for invasive aspergillosis in immunocompromised patients [Cochrane protocol]
- Bilingual Status
- complete